{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:47:56Z","timestamp":1787028476666,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Institutes of Health\/National Eye Institute","doi-asserted-by":"publisher","award":["R01EY015130"],"award-info":[{"award-number":["R01EY015130"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health\/National Eye Institute","doi-asserted-by":"publisher","award":["R01EY017011"],"award-info":[{"award-number":["R01EY017011"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health\/National Eye Institute","doi-asserted-by":"publisher","award":["F30EY032311"],"award-info":[{"award-number":["F30EY032311"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health\/National Eye Institute","doi-asserted-by":"publisher","award":["P30EY014800"],"award-info":[{"award-number":["P30EY014800"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health Core","doi-asserted-by":"publisher","award":["R01EY015130"],"award-info":[{"award-number":["R01EY015130"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health Core","doi-asserted-by":"publisher","award":["R01EY017011"],"award-info":[{"award-number":["R01EY017011"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health Core","doi-asserted-by":"publisher","award":["F30EY032311"],"award-info":[{"award-number":["F30EY032311"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Institutes of Health Core","doi-asserted-by":"publisher","award":["P30EY014800"],"award-info":[{"award-number":["P30EY014800"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research to Prevent Blindness","award":["R01EY015130"],"award-info":[{"award-number":["R01EY015130"]}]},{"name":"Research to Prevent Blindness","award":["R01EY017011"],"award-info":[{"award-number":["R01EY017011"]}]},{"name":"Research to Prevent Blindness","award":["F30EY032311"],"award-info":[{"award-number":["F30EY032311"]}]},{"name":"Research to Prevent Blindness","award":["P30EY014800"],"award-info":[{"award-number":["P30EY014800"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The pathophysiology of retinopathy of prematurity (ROP) is postulated to first involve delayed intraretinal vascularization, followed by intravitreal neovascularization (IVNV). Although intravitreal agents that reduce the bioactivity of vascular endothelial growth factor (VEGF) are used to treat IVNV, concerns exist regarding their effects on intraretinal vascularization. In an experimental ROP model, VEGF receptor 2 (VEGFR2) knockdown in retinal endothelial cells reduced IVNV and promoted intraretinal vascularization, whereas knockdown of a downstream effector, signal transducer and activator of transcription 3 (STAT3) in retinal endothelial cells only reduced IVNV. In this study, we tested the hypothesis that the different pathways involved in VEGF-triggered VEGFR2 signaling and VEGF-triggered STAT3 signaling in retinal endothelial cells would allow us to delineate signaling pathways involved in IVNV from those involved in intraretinal vascularization in ROP. To address our hypothesis, we used RNA-sequencing and pathway enrichment analysis to determine changes in the transcriptome of cultured human retinal microvascular endothelial cells (HRMECs). Of the enriched pathways, inactivation of oncostatin M signaling was predicted by either KDR or STAT3 knockdown in the presence of VEGF. Activation of kinetochore metaphase signaling was predicted by KDR knockdown, whereas inactivation was predicted by STAT3 knockdown in the presence of VEGF. Inactivation of signaling by the Rho family of GTPases was predicted by KDR knockdown, but activation was predicted by STAT3 knockdown in the presence of VEGF. Taken together, our data identified unique signaling pathway differences between VEGF-triggered VEGFR2 and VEGF-triggered STAT3 in HRMECs that might have implications in ROP.<\/jats:p>","DOI":"10.3390\/ijms23137354","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T22:50:46Z","timestamp":1656888646000},"page":"7354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["RNA-Seq Provides Insights into VEGF-Induced Signaling in Human Retinal Microvascular Endothelial Cells: Implications in Retinopathy of Prematurity"],"prefix":"10.3390","volume":"23","author":[{"given":"Aniket","family":"Ramshekar","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Bretz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth","family":"Hartnett","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, 65 Mario Capecchi Dr, Salt Lake City, UT 84132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: A global perspective of the epidemics, population of babies at risk and implications for control","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum. Dev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003). Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol., 121, 1684\u20131694.","DOI":"10.1001\/archopht.121.12.1684"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity","volume":"364","author":"Kennedy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very Late Reactivation of Retinopathy of Prematurity after Monotherapy with Intravitreal Bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Saint-Geniez, M., Maharaj, A.S., Walshe, T.E., Tucker, B.A., Sekiyama, E., Kurihara, T., Darland, D.C., Young, M.J., and D\u2019Amore, P.A. (2008). Endogenous VEGF is required for visual function: Evidence for a survival role on muller cells and photoreceptors. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003554"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41598-018-20278-4","article-title":"Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Muller cells maintains retinal function by triggering different signaling mechanisms","volume":"8","author":"Becker","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1167\/iovs.13-13755","article-title":"Targeting Muller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity","volume":"55","author":"Jiang","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrm.2016.87","article-title":"Mechanisms and regulation of endothelial VEGF receptor signalling","volume":"17","author":"Simons","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1203\/00006450-199412000-00007","article-title":"Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat","volume":"36","author":"Penn","year":"1994","journal-title":"Pediatr. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10456-018-9618-5","article-title":"Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy","volume":"21","author":"Simmons","year":"2018","journal-title":"Angiogenesis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ajpath.2011.11.031","article-title":"VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression","volume":"180","author":"Wang","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1167\/iovs.08-3256","article-title":"The role of supplemental oxygen and JAK\/STAT signaling in intravitreous neovascularization in a ROP rat model","volume":"50","author":"Byfield","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_17","first-page":"194","article-title":"Multi-perspective quality control of Illumina RNA sequencing data analysis","volume":"16","author":"Sheng","year":"2017","journal-title":"Brief Funct. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"796143","DOI":"10.3389\/fped.2021.796143","article-title":"Vascular Endothelial Growth Factor Signaling in Models of Oxygen-Induced Retinopathy: Insights into Mechanisms of Pathology in Retinopathy of Prematurity","volume":"9","author":"Ramshekar","year":"2021","journal-title":"Front. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"ref_20","first-page":"2027","article-title":"Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity","volume":"9","author":"Arambulo","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","article-title":"Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity","volume":"97","author":"Castellanos","year":"2013","journal-title":"Br. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Writing Committee for the Pediatric Eye Disease Investigator Group, Hartnett, M.E., Wallace, D.K., Dean, T.W., Li, Z., Boente, C.S., Dosunmu, E.O., Freedman, S.F., Golden, R.P., and Kong, L. (2022). Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor after Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. JAMA Ophthalmol., 140, 337\u2013344.","DOI":"10.1001\/jamaophthalmol.2022.0030"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmet.2021.01.011","article-title":"Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition","volume":"33","author":"Tsuruda","year":"2021","journal-title":"Cell Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41390-020-0793-x","article-title":"Transcriptome analysis reveals dysregulation of genes involved in oxidative phosphorylation in a murine model of retinopathy of prematurity","volume":"88","author":"Zasada","year":"2020","journal-title":"Pediatr. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e129224","DOI":"10.1172\/jci.insight.129224","article-title":"Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model","volume":"4","author":"Shaw","year":"2019","journal-title":"JCI Insight"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15313","DOI":"10.1038\/s41598-021-94500-1","article-title":"Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)","volume":"11","author":"Jaszai","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1167\/iovs.01-1193","article-title":"Role for Extracellular Signal-Responsive Kinase-1 and -2 in Retinal Angiogenesis","volume":"44","author":"Bullard","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41390-019-0598-y","article-title":"Short- and long-term impact of hyperoxia on the blood and retinal cells\u2019 transcriptome in a mouse model of oxygen-induced retinopathy","volume":"87","author":"Zasada","year":"2020","journal-title":"Pediatr. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kusuhara, S., Fukushima, Y., Fukuhara, S., Jakt, L.M., Okada, M., Shimizu, Y., Hata, M., Nishida, K., Negi, A., and Hirashima, M. (2012). Arhgef15 promotes retinal angiogenesis by mediating VEGF-induced Cdc42 activation and potentiating RhoJ inactivation in endothelial cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0045858"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3109\/02713683.2011.593110","article-title":"RhoA activation and effect of Rho-kinase inhibitor in the development of retinal neovascularization in a mouse model of oxygen-induced retinopathy","volume":"36","author":"Fang","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1167\/iovs.14-14217","article-title":"Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-beta\/delta","volume":"55","author":"Suarez","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Kramer","year":"2014","journal-title":"Bioinformatics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:41:42Z","timestamp":1760139702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/13\/7354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":36,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23137354"],"URL":"https:\/\/doi.org\/10.3390\/ijms23137354","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}